DGAP-News: Carl Zeiss Meditec achieves further significant growth in revenue and order intake after nine months of 2021/22

Carl Zeiss Meditec generated revenue of 1,332.9m in the first nine months of fiscal year 2021/22 (prior year: 1,198.2m), corresponding to an increase of 11.2% (adjusted for currency effects: +9.8%) compared with the same period of the prior year.

Information
Retrieved on: 
Friday, August 5, 2022 - 7:01am
⚠ generated by AI ↴
Organisation: 
Stock Symbol: 
Content
Key Points: 
  • Carl Zeiss Meditec generated revenue of 1,332.9m in the first nine months of fiscal year 2021/22 (prior year: 1,198.2m), corresponding to an increase of 11.2% (adjusted for currency effects: +9.8%) compared with the same period of the prior year.
  • Order intake increased at a much higher rate than revenue, rising 36.0% to 1,750.5m (prior year: 1,287.6m).
  • I am therefore highly satisfied with the very solid revenue growth and the even stronger order intake.
  • Revenue growth, as well as in particular the increasing share of recurring revenue and favorable currency effects, had a positive impact on operating result.



DGAP-News: Carl Zeiss Meditec AG

/ Key word(s): 9 Month figures/Quarter Results


Carl Zeiss Meditec achieves further significant growth in revenue and order intake after nine months of 2021/22

05.08.2022 / 07:00

The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec achieves further significant growth in revenue and order intake after nine months of 2021/22
 

JENA, 5 August 2022

Carl Zeiss Meditec generated revenue of €1,332.9m in the first nine months of fiscal year 2021/22 (prior year: €1,198.2m), corresponding to an increase of 11.2% (adjusted for currency effects: +9.8%) compared with the same period of the prior year. Order intake increased at a much higher rate than revenue, rising 36.0% to €1,750.5m (prior year: €1,287.6m). Earnings before interest and taxes (EBIT) at €275.9m were only slightly below the previous year's level of €282.8m, which had still benefited considerably from lower operating costs during the COVID-19 pandemic. The EBIT margin was 20.7% (prior year: 23.6%). The adjusted EBIT margin was 21.2% (prior year: 23.9%). 

Dr. Markus Weber: “In the last few months, the continuing tense global supply chain situation and the COVID-19 lockdown in Shanghai have presented us with major challenges, but our teams have once again managed to overcome them superbly. I am therefore highly satisfied with the very solid revenue growth and the even stronger order intake. Our markets and our portfolio are developing at a strong pace.”

Contributions to growth from all strategic business units and regions

Revenue in the Ophthalmic Devices strategic business unit (SBU) increased by 11.2% in the first nine months of fiscal year 2021/22 (adjusted for currency effects: +10.0%) to €1,027.2m (prior year: €923.4m). Recurring revenue from consumables, implants and services once again contributed significantly to the growth. The equipment business continued to be impacted by supply chain bottlenecks. Orders received in the Ophthalmic Devices SBU increased disproportionately to revenue. Revenue in the Microsurgery SBU increased by 11.2% (adjusted for currency effects: +9.2%) to €305.7m (prior year: €274.8m).  Orders received in the Microsurgery SBU likewise increased at a much higher rate than revenue.

Revenue in the EMEA[1]region increased by 5.3% (adjusted for currency effects: +6.5%) to €334.2m (prior year: €317.3m). Orders received in the core European markets exhibited a very positive trend.

Revenue in the Americas region increased by 8.0% (adjusted for currency effects: +1.1%) to €330.4m (prior year: €305.9m). Contributors to this are both the stable development in the USA as well as a further recovery in the countries of South America.

In the APAC[2]region, revenue increased to €668.3m, compared with €575.0m in the prior year (+16.2%; adjusted for currency effects: +16.2%[3]). The strongest contributions to growth came from China and India. The Japanese market also recorded growth.

Solid EBIT margin despite scheduled high investments

The operating result (earnings before interest and taxes: EBIT) was close to the previous year’s level at €275.9m in the first nine months of fiscal year 2021/22 level (prior year: €282.8m). Revenue growth, as well as in particular the increasing share of recurring revenue and favorable currency effects, had a positive impact on operating result. Scheduled larger investments in Sales & Marketing and Research & Development had an adverse effect on operating result. EBIT of the previous year had benefited in particular from low sales & marketing costs during the COVID-19 pandemic. The EBIT margin decreased to 20.7% (previous year: 23.6%). Adjusted for special effects, this amounted to 21.2% (prior year: 23.9%). Earnings per share increased to €2.14 (prior year: €2.04).

The company's outlook for fiscal year 2021/22 is substantiated: Revenue is expected to be at least around €1.8b, while EBIT margin in fiscal 2021/22 should be in the upper range of the previous forecast range of 19-21%. The forecasts for revenue and EBIT assume that the COVID-19 situation in China and the global supply chain situation do not deteriorate further in the course of the fourth quarter of 2021/22.

In the medium term, the EBIT margin is expected to develop to a level sustainably above 20%. The rising proportions of recurring revenue are making a positive contribution to this. Conversely, scheduled strategic investments in Research & Development and Sales & but Marketing remain high.

 

Revenue by strategic business unit

All figures in €m 9 months

2021/22
9 Months

2020/21
Change from

previous year
Change from prior year

(currency-adjusted)
Ophthalmic Devices 1,027.2 923.4 +11.2% +10.0%
Microsurgery 305.7 274.8 +11.2% +9.2%
Overall group 1,332.9 1,198.2 +11.2% +9.8%

 

Revenue by region

All figures in €m 9 months

021/22
9 Months

2020/21
Change from

previous year
Change from prior year

(currency-adjusted)
EMEA 334.2 317.3 +5.3% +6.5%
Americas 330.4 305.9 +8.0% +1.1%
APAC 668.3 575.0 +16.2% +16.2%
Overall group 1,332.9 1,198.2 +11.2% +9.8%

 

Further information on our publication and the Analyst Conference Call on the results for the first nine months of fiscal year 2021/22 can be found at

https://www.zeiss.de/meditec-ag/investor-relations/finanzkalender/telefonkonferenzen.html

 

Contact for investors and press

Sebastian Frericks

Director of Group Finance & Investor Relations, Carl Zeiss Meditec AG

Phone: 03641 220-116

Email: investors.meditec@zeiss.com

 

www.zeiss.com/press

 

 

[1] Europe, Middle East, Africa

[2] Asia/Pacific region

[3] In the APAC region, invoicing to distributors is largely done in euros.




05.08.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1413825



 
End of News DGAP News Service

1413825  05.08.2022 

fncls.ssp?fn=show_t_gif&application_id=1413825&application_name=news&site_id=jotup